Sfoglia per AUTORE
VICI P
Collezione AO Cuneo

  

Items : 17

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.

2021
AO Cuneo

Vici P; Ciliberto G; Sanguineti G; Di Leo A; De Maria R; Daralioti T; Sperduti I; Perracchio L; di Benedetto A; Del Medico P; Roselli M; Vaccaro A; Garufi C; Cazzaniga M; Lorusso V; Russo A; Pistelli M; Giotta F; Meattini I; Garrone O; Paris I; Sarobba G; Veltri E; Corsi D; D'Ostilio N; Grassadonia A; Valerio MR; Mirabelli R; Fabbri MA; et alii...

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. in Breast cancer research and treatment / Breast Cancer Res Treat. 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21.

2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Vallini I; Clivio L; Di Mauro P; Cogliati V; Capici S; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Spadaro P; Taverniti C; Scognamiglio G; Sarobba MG; Schintu MG; Saracchini S; Santini D; Riccardi F; Putzu C; Nicolini M; Musolino A; Sarti S; Marchetti P; Grassadonia A; Leonardi V; Giovanardi F; Gianni L; Generali D; et alii...

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. in Journal of cellular physiology / J Cell Physiol. 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15.

2020
AO Cuneo

Vici P; Giordano A; Barba M; Mazzotta M; Sperduti I; Ciliberto G; Villa A; Risi E; De Maria R; Del Medico P; Generali D; Meattini I; Livi L; Garrone O; Baldini E; Zamagni C; Pistelli M; Cannita K; Valerio MR; Berardi R; Russo A; Ricciardi G; Adamo V; Ficorella C; Roselli M; Lorusso V; Landucci E; Paris I; Giotta F; et alii...

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.

2020
AO Cuneo

Mustacchi G; Pronzato P; Torri V; Marchetti P; Montemurro F; Riccardi F; Romagnoli E; Bisagni G; Livi L; Natoli C; Donadio M; Biganzoli L; Del Mastro L; Clivio L; Giordano M; Frassoldati A; Scavelli C; Ferzi A; Schirone A; Palumbo R; Gebbia V; Fabi A; Santini D; Turletti A; Porpiglia M; Atzori F; Blasi L; De Laurentiis M; Artale S; et alii...

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.

2020
AO Cuneo

Roselli M; Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; et alii...

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. in Vaccines / Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191.

2020
AO Cuneo

Polimeni A; Vici P; Salati M; Ronzino G; Pizzuti L; Cortellini A; Cassano A; Di Dio C; Cirillo A; Mammone G; Roberto M; Cerbelli B; Sciattella P; Pomati G; Mezi S; Botticelli A; Merlano MC; Nuti M; Marchetti P;

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. in International journal of cancer / Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7.

2020
AO Cuneo

Vici P; Di Leo A; Barba M; Villa A; Ciliberto G; Sperduti I; De Maria R; Risi E; Generali D; De Tursi M; Sarobba G; Del Medico P; Meattini I; Desideri I; Livi L; Baldini E; Di Cocco B; Foglietta J; Greco F; Zamagni C; Garrone O; D'Ostilio N; Sini V; Cannita K; Adamo V; Ricciardi GRR; Fiorio E; Pistelli M; Russo A; et alii...

The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial in Journal of Clinical Oncology

2020
AO Cuneo

Marchetti P; Nuti M; Merlano MC; Roberto M; Cirillo A; Mammone G; Cassano A; Di Dio C; Cortellini A; Pizzuti L; Ronzino G; Salati M; Vici P; Sciattella P; Pomati G; Mezi S; Botticelli A;

Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. in The breast journal / Breast J. 2019 May;25(3):444-449. doi: 10.1111/tbj.13240. Epub 2019 Apr 1.

2019
ASL Torino 5
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli

Bonzano A; Milani A; D'Alonzo A; Bellini E; Pizzuti L; Barone C; Del Mastro L; Garrone O; Airoldi M; Vici P; Becco P; Martinello R; Montemurro F;

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. in Breast (Edinburgh, Scotland) / Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22.

2019
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Città di Torino
ASL Vercelli

Clivio L; Cavanna L; Ciccarese M; Vici P; Valerio MR; Valenza R; Turletti A; Tralongo P; Toniolo D; Taverniti C; Spadaro P; Scognamiglio G; Schintu MG; Sarobba MG; Saracchini S; Santini D; Riccardi F; Nicolini M; Putzu C; Musolino A; Melegari E; Marchetti P; Leonardi V; Grassadonia A; Giovanardi F; Generali D; Gianni L; Gebbia V; Gambaro AR; et alii...

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. in Clinical breast cancer / Clin Breast Cancer. 2019 Aug;19(4):e501-e510. doi: 10.1016/j.clbc.2019.05.006. Epub 2019 May 18.

2019
AO Cuneo

Valerio M; Marchetti F; Russo A; Barni S; Galanti D; Leonardi V; Cavanna L; Foglietta J; Turazza M; Cretella E; Laudadio L; Vici P; Garrone O; Tarenzi E; Frassoldati A; La Verde N; Fabi A; Moroso S; Gori S; Puglisi F; Lunardi G; Alongi F; Inno A;

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AO Cuneo

Clivio L; Torri On Behalf Of The Eva Study Group V; Frassoldati A; Scavelli C; Palumbo R; Ferzi A; Schirone A; Cursano MC; Fabi A; Gebbia V; Benedetto C; Atzori F; Turletti A; Blasi L; Piezzo M; Artale S; Mentuccia L; La Verde N; Bianchi G; Musolino A; Vici P; Maur M; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AO Cuneo

Torri V; Frassoldati A; Clivio L; Scavelli C; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Benedetto C; Cursano MC; Turletti A; Atzori F; Artale S; Blasi L; Piezzo M; Bianchi G; Maur M; La Verde N; Mentuccia L; Vici P; Musolino A; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AO Cuneo

Torri On Behalf Of The Eva Study Group V; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Cursano MC; Turletti A; Benedetto C; Atzori F; Piezzo M; Artale S; Blasi L; La Verde N; Bianchi G; Maur M; Mentuccia L; Vici P; Musolino A; Garrone O; Pistelli M; Zambelli A; Febbraro A; Generali D; Diodati L; Arcangeli V; et alii...

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

2017
AO Cuneo
ASL Città di Torino

Clivio L; Zambelli A; Blasi L; Torri V; Sartori D; Scavelli C; Schirone A; Turletti A; Vici P; Valerio MR; Palumbo R; Pistelli M; Musolino A; Porpiglia M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Moretti G; Maur M; Michelotti A; La Verde N; Generali D; Gebbia V; Garrone O; Fumagalli A; Frassoldati A; Ficorella C; et alii...

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. in Oncotarget / Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

2017
AO Cuneo

Ciliberto G; Di Cocco B; Marolla P; Sanguineti G; Garrone O; Della Giulia M; Laudadio L; Greco F; Barni S; Lorusso V; Cannita K; Russo A; Adamo V; Giotta F; Tomao S; Ficorella C; Alberti AM; Landucci E; Rossi E; Barba M; Maugeri-Saccà M; Sini V; Mauri M; D'Onofrio L; Scinto AF; Zampa G; Bertolini I; Botticelli A; Piacentini F; et alii...

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.

2015
ASL Cuneo 1
AO Cuneo
AOU Novara

Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L; Gamucci T; Evangelisti L; Barni S; Saracchini S; Amaducci L; Santini D; Fabi A; Garrone O; Frassoldati A; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Spazzapan S; Iezzi L; De Simone V; Duranti S; Cavazzini MG; Turazza M; Gubiotti M; Foglietta J; et alii...